Help us: Donate
Follow us on:

Re-engineering Macrophages to Eat Cancer Cells


Today, we have a new study where researchers have created immune cells that ignore the way cancer tries to hide from detection.

Hiding in plain sight

Macrophages are one of the types of immune cell and are responsible for dealing with dangerous cells, such as those which have become cancerous. The problem is, most cancer cells bypass the immune system by fooling the immune cells into leaving them alone. Cancer cells present certain molecules on their surface that act like a “do not eat me” signal to macrophages which would otherwise engulf and digest them.

This ability to evade detection by the immune system is one of the reasons cancer is hard to treat effectively. Immune cells are patrolling the body constantly and looking at the surfaces of cells for the telltale signs that something is wrong, so when cancer cells hide those signs and pretend to be healthy cells the immune system cannot deal with them. Without the immune system taking action, there is nothing to stop cancer spreading beyond control and killing the patient.

Re-engineering macrophages

The researchers in this new study have demonstrated that they can produce re-engineered macrophages that are able to ignore this “do not eat me” signal that cancer uses to hide[1]. In the past there have been attempts at doing this, though they proved to be harmful to healthy cells and did not make it to the clinic. This new approach avoids damage to healthy cells and is a step in the right direction for cancer immunotherapy.

The research team were able to re-engineer macrophages that had the ability to travel through the body of a mouse, penetrate solid tumors and engulf the human cancer cells inside.

Other therapies using modified T-Cells have also recently enjoyed success on the cancer immunotherapy front, in particular for blood cancers, referred to as liquid tumors. However, tumors in other tissues can be more solid, which makes it difficult for T-cells to invade the tumor as they cannot penetrate the outside.

The “Do not eat me” signal cancer uses to survive

It has been known for decades that macrophages can easily penetrate such tumors, and due to this, macrophage-based cancer therapies were tested years ago. Unfortunately they were not effective in destroying the cancerous cells. It is now apparent that this is because the cancer cells were using the “do not eat me” signals healthy cells use to avoid destruction.

The research team has demonstrated that a protein called CD47 on human cells acts as a “marker of self” by interacting with a protein on the surface of macrophages called SIRPA. When SIRPA comes into contact with CD47 on another cell, it tells the macrophage not to engulf the other cell and marks it as friendly, even if that cell is cancerous. The researchers thought that regulating this protein may be the key to using macrophage-based therapies effectively.

In the past people have attempted to use antibodies that block CD47 and stop it interacting with SIRPA on macrophages. However, such attempts in the past have caused rapid loss of circulating blood cells because the macrophages attack healthy cells too. This lead to anemia and even death from autoimmune disease in the mice tested.

The researchers here have bypassed this problem by taking young macrophages and blocked their SIRPA directly. They also injected various antibodies that bind to cancer cells to help activate the macrophages and encourage them to invade the tumor. The researchers observed that the macrophages circulated in the body but accumulated at the location of tumors where they began engulfing cancer cells.

After two injections the cancer cells were reduced 100-fold in size, going from the size of a dime to an eighty percent decrease in size. Also importantly, the researchers observed that blood cells were not affected by this treatment, suggesting the approach is safe.

Finally, the researchers noted that the macrophages eat the cancer cells for about a week after injection but then stop. However, additional injections continue to safely induce tumor regression. The team is now working on ways make the effects longer lasting whilst minimizing side effects such as damage to healthy cells.


Marrow-derived macrophages are highly phagocytic, but whether they can also traffic into solid tumors and engulf cancer cells is questionable, given the well-known limitations of tumor-associated macrophages (TAMs). Here, SIRPα on macrophages from mouse and human marrow was inhibited to block recognition of its ligand, the “marker of self” CD47 on all other cells. These macrophages were then systemically injected into mice with fluorescent human tumors that had been antibody targeted. Within days, the tumors regressed, and single-cell fluorescence analyses showed that the more the macrophages engulfed, the more they accumulated within regressing tumors. Human-marrow-derived macrophages engorged on the human tumors, while TAMs were minimally phagocytic, even toward CD47-knockdown tumors. Past studies had opsonized tumors in situ with antibody and/or relied on mouse TAMs but had not injected SIRPα-inhibited cells; also, unlike past injections of anti-CD47, blood parameters remained normal and safe. Consistent with tumor-selective engorge-and-accumulate processes in vivo, phagocytosis in vitro inhibited macrophage migration through micropores that mimic features of dense 3D tissue. Accumulation of SIRPα-inhibited macrophages in tumors favored tumor regression for 1-2 weeks, but donor macrophages quickly differentiated toward non-phagocytic, high-SIRPα TAMs. Analyses of macrophages on soft (like marrow) or stiff (like solid tumors) collagenous gels demonstrated a stiffness-driven, retinoic-acid-modulated upregulation of SIRPα and the mechanosensitive nuclear marker lamin-A. Mechanosensitive differentiation was similarly evident in vivo and likely limited the anti-tumor effects, as confirmed by re-initiation of tumor regression by fresh injections of SIRPα-inhibited macrophages. Macrophage motility, phagocytosis, and differentiation in vivo are thus coupled.


Immunotherapy represents one of the most promising areas of cancer research and it is our hope that in the not too distant future it will become the standard of care, replacing harsh chemotherapy and radiotherapy which appear to do more harm than good.

Cancer is the poster child of aging diseases, and whilst younger people do get it too, it remains predominantly an age-related disease caused by genomic instability, a primary hallmark of aging. If we are to hope for healthier and longer lives beyond the current norms that medicine allows now, then we must find robust solutions to cancer. Immunotherapy could well be that solution, and if recent news is anything to go by, we may soon win the war on cancer. Let’s hope so.


[1] Alvey, C. M., Spinler, K. R., Irianto, J., Pfeifer, C. R., Hayes, B., Xia, Y., … & Tewari, M. (2017). SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors. Current Biology.

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
  1. jimofoz
    July 22, 2017

    So the difference with past macrophage therapies is that rather than using an antibody to block CD47 on cancer cells (but also unfortunately other cells such as blood cells) the researchers block the SIRPA ligand on the macrophages before injecting them?

    Does this stop the macrophages from attacking blood cells in some way that anti CD47 antibodies do not? Or is it the addition of antibodies to tumor antigens that limits off target effects of the marcrophages?

    I’ve got to wonder if gene editing of the macrophages to introduce a second generation Chimeric Antigen Receptor whose signal blocks the signal from the SIRPA ligand might not be a better approach? You could then inject any level of macrophages and never have them attack blood cells, whereas with macrophages with SIRPA ligands blocked by antibodies there must still be some potential for off target effects before therapeutic levels are reached.

Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Want the latest longevity news? Subscribe to our Newsletter!